Skip to main content
Norris Cotton Cancer Center
In This Section

Immunology & Cancer Immunotherapy Program Themes and Highlights

Members of the Immunology and Cancer Immunotherapy Research Program are investigating the following areas:

  • Immune regulation
  • Alteration of the tumor microenvironment (TME) for therapeutic benefit
  • Translational Immunotherapy

Program highlights

Immunology and Cancer Immunotherapy Program Entrepreneurship

The Immunology and Cancer Immunotherapy Program has a notable history of entrepreneurship, with current and former members (Drs. Michael Fanger and Paul Guyre) having founded Medarex, in 1987, and Genmab in 1999.

Medarex (purchased by Bristoll Meyers Squib in 2009) developed the first immune checkpoint inhibitor drugs (ipilimumab and nivolumab) for cancer patients.

ICIP scientists currently work closely with industrial partners Immunext, Inc.; Celdara Medical, LLC; and Occulo Bio to translate immunotherapeutic discoveries to the clinic.

Articles featuring ICIP investigators and their recent work